相关实验视频

Updated: Sep 9, 2025

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

发现具有广谱抗增殖活性的基于Pyrazolo[1,5-a]的选择性HDAC6抑制剂

Wendeng Li^1,2, Chunhong Ma³, Changchun Ye⁴

¹Department of Thoracic Surgery, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710004, Shaanxi, China.

|August 29, 2025

概括

新的pyrazolo[1,5-a]pyrimidine类似物被合成为癌症治疗的选择性基因脱乙酶6 (HDAC6) 抑制剂. 化合物8e显示出强大的HDAC6抑制和对癌细胞系的显著抗增殖活性.

科学领域:

医学化学
药理学
癌症生物学

背景情况:

选择性基因脱乙酶6 (HDAC6) 抑制剂在癌症治疗中具有独特的治疗效益.
酸组是抑制HDAC6的关键药物.

研究的目的:

设计和合成新型的pyrazolo[1,5-a]pyrimidine衍生物,其中包括酸部分.
评估这些化合物对HDAC6和其他HDAC异型的抑制活性和选择性.
评估最强效化合物对癌细胞系的抗增殖作用.

主要方法:

合成十三种pyrazolo[1,5-a]pyrimidine类似物
酶测试以确定HDAC6和HDAC1抑制的IC50值.
针对HL-60和SK-MEL-2癌细胞系的抗增殖试验.
分子对接模拟以预测结合相互作用.

主要成果:

化合物8e,N-基-4-基-7-基) 醇[1,5-a]基-5-基) 氨基) 甲基) 胺被确定为最强效的模拟物.
8e具有显著的HDAC6抑制,IC50为3. 84nM,对HDAC1的选择性是412倍.
对HL-60 (IC50=0. 2nM) 和SK- MEL-2 (IC50=0. 35nM) 细胞系表现出强烈的抗增殖活性.
分子对接证实了在HDAC6结合部位内的pyrazolo[1,5-a]pyrimidine核心的有利相互作用.

结论:

这种新型的pyrazolo[1,5-a]pyrimidine支架有效地结合了酸药,以强烈和选择性地抑制HDAC6.
化合物8e是作为针对HDAC6的抗癌治疗剂进一步开发的有希望的首选药物.
这些发现支持选择性HDAC6抑制剂在癌症治疗策略中的潜力.

关键词:

HDAC6 抑制剂抗扩散药物醇胺选择性结构和活动关系

更多相关视频

Assays for Validating Histone Acetyltransferase Inhibitors

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique

Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique

Published on: January 14, 2016

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...